Clinical Trials Logo

CNS Tumor clinical trials

View clinical trials related to CNS Tumor.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05952687 Withdrawn - Rhabdoid Tumor Clinical Trials

Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors

Start date: March 2024
Phase: Phase 1
Study type: Interventional

iSTAR is an open-label, multi-center, phase 1b study of oral XPO1 inhibitor selinexor and oral MDM2 inhibitor idasanutlin in children with progressive or recurrent atypical teratoid/rhabdoid tumors (AT/RT), malignant rhabdoid tumors (MRT) and synchronous/metachronous rhabdoid tumors. Primary Objectives - To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of combination treatment with oral idasanutlin and selinexor in children with recurrent or progressive AT/RT or MRT. - To characterize the plasma pharmacokinetics of oral idasanutlin and selinexor in children with recurrent or progressive AT/RT or MRT, to assess potential covariates to explain the inter- and intra-individual pharmacokinetic variability. Secondary Objectives - Evaluate safety of the combination treatment with oral idasanutlin and selinexor in children - Evaluate efficacy of the combination treatment of idasanutlin and selinexor as measured by objective response (partial response [PR] or complete response [CR]) rate separately in progressive/relapsed AT/RT and progressive/relapsed MRT - Estimate progression-free and overall-survival separately in progressive/relapsed AT/RT and progressive/relapsed MRT

NCT ID: NCT05222165 Withdrawn - Clinical trials for Advanced Solid Tumor

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

NEWEL
Start date: October 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib. The phase 2 study will evaluate efficacy and safety of infigratinib.